Latest Announcements

BSE & NSE corporate filings with AI summaries

NSEPress Release▲ PositiveM&A19 Aug 2026

HEG Limited

Press Release

HEG Limited has received approval from the National Company Law Tribunal (NCLT) for its demerger scheme, paving the way for two independently listed companies. Shareholders will receive one equity share of HEG Graphite Limited for every one share held in HEG Limited.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A19 Aug 2026

HEG Ltd

Attached

HEG Ltd receives NCLT approval for demerger scheme, creating two independently listed companies with a 1:1 share ratio. The restructuring aims to unlock long-term value for shareholders by giving them direct exposure to a mature graphite electrode business and a fast-scaling growth platform focused on advanced materials, battery energy solutions, and renewable energy.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A19 Aug 2026

TVS Holdings Ltd

Approval of the Scheme of Arrangement between TVS Holdings Limited and its shareholders

TVS Holdings Ltd has received approval from the National Company Law Tribunal for its Scheme of Arrangement, which involves distributing surplus funds to shareholders by issuing fully paid-up Preference Shares. The Scheme was approved with 99% of equity shareholders voting in favor. The Company will now take further steps to give effect to the Scheme.

Read more →📎 1 attachment
NSEGeneral Updates▲ PositiveM&A19 Aug 2026

TVS Holdings Limited

General Updates

TVS Holdings Limited has informed the Exchange about approval of the Scheme of Arrangement between TVS Holdings Limited and its shareholders.

Read more →📎 1 attachment
NSEPress Release▲ PositiveM&A19 Aug 2026

Paisalo Digital Limited

Press Release

Paisalo Digital Limited has entered a Memorandum of Understanding with LoanKhata for a proposed co-lending partnership worth up to ₹1,000 crore. The partnership aims to strengthen Paisalo's three-year roadmap of doubling AUM, income, and PAT while preserving asset quality.

Read more →📎 1 attachment
NSEPress Release▲ PositiveM&A18 Aug 2026

Jubilant Ingrevia Limited

Press Release

Jubilant Ingrevia Limited has entered into a binding agreement with Zettaone Technologies India Pvt. Ltd. for the acquisition of a 40% strategic stake for INR 189.2 crore, aligning with the company's Pinnacle growth strategy and providing a strong platform for its play in Electronics Development and Manufacturing Services (EDMS) space.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A18 Aug 2026

Jubilant Ingrevia Ltd

Press Release

Jubilant Ingrevia Ltd has entered into a binding agreement with Zettaone Technologies India Pvt Ltd for the acquisition of a 40% strategic stake for INR 189.2 crore. The proposed investment is aligned with the Company's Pinnacle growth strategy and provides a strong platform for its play in Electronics Development and Manufacturing Services (EDMS) space.

Read more →📎 1 attachment
NSEGeneral Updates▲ PositiveM&A18 Aug 2026

Jubilant Ingrevia Limited

General Updates

Jubilant Ingrevia Limited has entered into a binding agreement with Zettaone Technologies India Pvt Ltd to acquire a 40% strategic stake for INR 189.2 crore, aligning with its Pinnacle growth strategy and expanding its presence in the Electronics Development and Manufacturing Services (EDMS) space.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A18 Aug 2026

Jubilant Ingrevia Ltd

The Board approved to enter into binding term sheet with Zettaone Technologies India Private Limited (Zettaone) for acquisition of 40% strategic equity stake in Zettaone.

Jubilant Ingrevia Ltd has entered into a binding term sheet with Zettaone Technologies India Private Limited for the acquisition of a 40% strategic equity stake in Zettaone for ₹189.2 Cr. The acquisition is aligned with the company's Pinnacle growth strategy and will enable Jubilant Ingrevia to deliver an integrated value proposition in electronics and semi-conductor space.

Read more →📎 1 attachment
NSEPress Release▲ PositiveM&A18 Aug 2026

Alivus Life Sciences Limited

Press Release

Alivus Life Sciences Limited has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. The acquisition will enable Alivus to leverage its core portfolio selectively into advanced formulation development and expand its global customer base in the generic pharmaceutical segment.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A18 Aug 2026

Alivus Life Sciences Ltd

Enclosed please find herewith Press Release with respect to Acquisition.

Alivus Life Sciences Ltd has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. The acquisition will enable Alivus to leverage its core portfolio selectively into advanced formulation development and expand its global customer base in the generic pharmaceutical segment.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A18 Aug 2026

Alivus Life Sciences Ltd

Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.

Alivus Life Sciences Ltd has announced the acquisition of 76% stake in IQGEN-X Pharma Private Limited for INR 9.12 crores, subject to customary adjustments. The acquisition is expected to provide a wider spectrum for the company to offer a complete end-to-end solution to its customers in both API and CDMO space.

Read more →📎 1 attachment
BSECompany Update▲ PositiveM&A18 Aug 2026

Infosys Ltd

Enclosed

Infosys Ltd has collaborated with Knorr-Bremse AG to accelerate AI-enabled enterprise transformation. The collaboration will help Knorr-Bremse AG simplify and modernize its IT landscape, improve service quality, and accelerate its shift toward a value-driven, future-ready IT operating model.

Read more →📎 1 attachment
NSEUpdates▲ PositiveM&A18 Aug 2026

Infosys Limited

Updates

Infosys Limited has announced a strategic collaboration with Knorr-Bremse AG to accelerate AI-enabled enterprise transformation. The collaboration will help Knorr-Bremse simplify and modernize its IT landscape, improve service quality, and accelerate its shift toward a value-driven, future-ready IT operating model.

Read more →📎 1 attachment
NSEAcquisition▲ PositiveM&A18 Aug 2026

Piramal Pharma Limited

Acquisition

Piramal Pharma Limited has acquired an additional 40.67% stake in Yapan Bio Private Limited, increasing its shareholding from 33.33% to 74.00%. The acquisition was completed for an aggregate cash consideration of approximately ₹76 crores. Yapan has ceased to be an associate company and has become a subsidiary of Piramal Pharma Limited.

Read more →📎 1 attachment